NeuroPace, Inc. to Present at 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
NeuroPace, Inc. to Present at 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
NeuroPace will present at the J.P. Morgan Healthcare Conference on January 15, 2025, discussing its epilepsy treatment innovations.
Quiver AI Summary
NeuroPace, Inc., a medical device company dedicated to improving the lives of people with epilepsy, announced that its management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025, in San Francisco, CA. The presentation is scheduled for 4:30 PM PT and will be available via live webcast, with a replay accessible for two weeks afterward on the company's investor website. NeuroPace is known for its RNS System, the first brain-responsive platform designed to deliver personalized treatment for drug-resistant epilepsy, aiming to enhance patient outcomes and potentially benefiting those with other brain disorders.
Potential Positives
- NeuroPace will present at a prominent industry event, the 43rd Annual J.P. Morgan Healthcare Conference, which can enhance visibility and credibility among investors and industry peers.
- The company is actively engaging with investors during the conference, potentially fostering better relationships and increasing investor interest.
- The RNS System, NeuroPace's innovative medical device, is highlighted as the first and only commercially available platform for real-time treatment of epilepsy, showcasing the company's leading position in the market.
- NeuroPace's focus on personalized, brain-responsive treatment aligns with trends in healthcare towards individualized patient care, which could attract interest from both investors and patients alike.
Potential Negatives
- None
FAQ
What is NeuroPace, Inc. focused on?
NeuroPace, Inc. is focused on transforming the lives of people living with epilepsy through innovative medical devices.
When will NeuroPace present at the J.P. Morgan Healthcare Conference?
NeuroPace will present at the J.P. Morgan Healthcare Conference on January 15, 2025, at 4:30 PM PT.
How can I access the NeuroPace presentation?
The presentation will be accessible via live webcast and a replay will be available for two weeks after.
What is the RNS System developed by NeuroPace?
The RNS System is the first brain-responsive platform that delivers personalized, real-time treatment at the source of seizures.
Where is NeuroPace, Inc. located?
NeuroPace, Inc. is based in Mountain View, California.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$NPCE Insider Trading Activity
$NPCE insiders have traded $NPCE stock on the open market 29 times in the past 6 months. Of those trades, 0 have been purchases and 29 have been sales.
Here's a breakdown of recent trading of $NPCE stock by insiders over the last 6 months:
- LTD. KCK has traded it 29 times. They made 0 purchases and 29 sales, selling 322,928 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$NPCE Hedge Fund Activity
We have seen 23 institutional investors add shares of $NPCE stock to their portfolio, and 43 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- KENT LAKE CAPITAL LLC added 500,625 shares (+77.8%) to their portfolio in Q2 2024
- ARMISTICE CAPITAL, LLC added 480,000 shares (+inf%) to their portfolio in Q3 2024
- DEUTSCHE BANK AG\ removed 241,429 shares (-36.9%) from their portfolio in Q3 2024
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 203,776 shares (-100.0%) from their portfolio in Q2 2024
- NORTHERN TRUST CORP added 117,647 shares (+279.0%) to their portfolio in Q3 2024
- EAM INVESTORS, LLC removed 75,625 shares (-100.0%) from their portfolio in Q2 2024
- JANE STREET GROUP, LLC removed 72,013 shares (-100.0%) from their portfolio in Q2 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
MOUNTAIN VIEW, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 43
rd
Annual J.P. Morgan Healthcare Conference at 4:30pm PT (7:30pm ET) on Wednesday, January 15, 2025, in San Francisco, CA. Management will also host investor meetings during the conference.
The presentation will be accessible via live webcast
here
. A webcast replay will be available for two weeks following the presentation in the
Events
section of NeuroPace's Investor website at
.
About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.
Investor Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
jfeffer@lifesciadvisors.com
